Lantheus Holdings, Inc.

Equities

LNTH

US5165441032

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
80.29 ^USD	-1.25%		+1.50%	+29.50%

27/06	Lantheus Holdings Acquires Global Rights to Life Molecular Imaging's RM2	MT
26/06	B. Riley Raises Price Target on Lantheus Holdings to $105 From $99, Maintains Buy Rating	MT

Certain shares of Lantheus Holdings, Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 14-JAN-2017.

January 14, 2017

Certain shares of Lantheus Holdings, Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 14-JAN-2017. These shares will be under lockup for 60 days starting from 15-NOV-2016 to 14-JAN-2017.

Latest news about Lantheus Holdings, Inc.

Lantheus Holdings Acquires Global Rights to Life Molecular Imaging's RM2	27/06	MT
B. Riley Raises Price Target on Lantheus Holdings to $105 From $99, Maintains Buy Rating	26/06	MT
Lantheus Makes $12 Million Investment in Radiopharm	21/06	MT
Radiopharm Theranostics Limited announced that it has received AUD 7.481259 million in funding from Lantheus Holdings, Inc.	20/06	CI
Lantheus? AI-Enabled aPROMISE Now Available on Siemens Healthineers? syngo.via platform	03/06	CI
Lantheus Holdings Insider Sold Shares Worth $1,454,989, According to a Recent SEC Filing	31/05	MT
Lantheus Holdings, Inc. Announces Management Appointments, Effective May 28, 2024	16/05	CI
Truist Raises Lantheus Holdings' PT to $94 From $82 After 'Solid' Q1 Beat, Keeps Buy Rating	03/05	MT
Lantheus Shares Rise After Reporting Higher Q1 Adjusted Earnings, Revenue; 2024 Guidance Raised	02/05	MT
Lantheus to Seek M&A Opportunities	02/05	CI
Transcript : Lantheus Holdings, Inc., Q1 2024 Earnings Call, May 02, 2024	02/05
Lantheus Holdings, Inc. Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024	02/05	CI
Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024	02/05	CI
(LNTH) LANTHEUS HOLDINGS Sees Q2 EPS Range $1.81 - $1.86	02/05	MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q1 Revenue $370M	02/05	MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q1 EPS $1.69	02/05	MT
Lantheus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
B. Riley Raises Price Target on Lantheus Holdings to $99 From $95, Keeps Buy Rating	18/04	MT
Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing	08/03	MT
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	06/03	CI
Lantheus Holdings Says FDA Approves Expanded Use of Definity in Pediatric Patients	04/03	MT
Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients	04/03	CI
Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	04/03	CI
Lantheus Names Amanda Morgan Chief Commercial Officer	28/02	MT
Truist Adjusts Price Target on Lantheus Holdings to $82 From $80, Maintains Buy Rating	26/02	MT

Chart Lantheus Holdings, Inc.

Duration

Period

More charts

Company Profile

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. The Company's pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Cardiolite, Automated Bone Scan Index (aBSI), Xenon Xe-133 Gas, Lu-DOTA-RM2, Ga-DOTA-RM2, and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Lantheus Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

80.29 USD

Average target price

105.5 USD

Spread / Average Target

+31.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
LANTHEUS HOLDINGS, INC.	+29.50%	5.57B
BIOMÉRIEUX	-11.73%	11.24B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-13.76%	7.29B
AUTOBIO DIAGNOSTICS CO., LTD.	-19.19%	3.68B
ANDON HEALTH CO., LTD.	+7.62%	2.58B
10X GENOMICS, INC.	-65.24%	2.33B
VITROLIFE AB	-10.63%	2.23B
MYRIAD GENETICS, INC.	+27.80%	2.21B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-19.12%	1.57B
SANSURE BIOTECH INC.	-10.08%	1.39B

Diagnostic & Testing Substances